CMPS · COMPASS Pathways Plc

The thesis

Compass Pathways' case rests on completing the New Drug Application (NDA) for its psilocybin treatment COMP360 in Q4 2026, which starts a priority-voucher review that targets one to two months. The shares closed at $11.81 on 27 October 2026, and the Q3 2026 results on 3 November 2026 show whether management still guides to a Q4 completion.

The company announced on 27 October 2026 that it will report third-quarter results on 3 November 2026. That moves the date from the ~5 November 2026 estimate in the previous note. No company release, SEC filing or regulatory action dated after 22 September 2026 has changed the clinical or regulatory picture. A search on 28 October 2026 found no report that the NDA is complete.

The narrative is maturing: the 52-week durability data of 9 September 2026 are well known, 17 brokerages cover the shares per MarketBeat, and attention has shifted to the filing date. The 14-day Relative Strength Index (RSI), a momentum gauge where readings under 30 are called oversold, was 51.0 on 27 October 2026, up from 25.7 on 14 October 2026. The shares sit 22.3% below their 52-week high of $15.19.

Bullish and bearish views on COMPASS Pathways Plc

The bull case on COMPASS Pathways Plc (CMPS), in brief: Review work has reached the label. The bear case: The shares sit well below September levels.

Bull case

• Review work has reached the label. At the Morgan Stanley Global Healthcare Conference on 22 September 2026, CEO Kabir Nath said the Food and Drug Administration (FDA) is reviewing a draft label and the Risk Evaluation and Mitigation Strategy (REMS) framework. He kept NDA completion in Q4 2026 and launch in the first half of 2027, per Yahoo Finance.
• The review clock is short by design. The FDA granted rolling review on 24 April 2026 and selected COMP360 for the Commissioner's National Priority Voucher programme in treatment-resistant depression. The programme targets a review of one to two months once the NDA is complete.
• Durability data reach one year. The company reported on 9 September 2026 that open-label COMP005 Part C results showed added benefit from a further dose, with durability out to 52 weeks.
• Cash funds the company into 2028. The Q2 release on 5 August 2026 reported $433.3 million of cash and equivalents at 30 June 2026 and guided funding into 2028.
• Analyst targets sit far above the price. MarketBeat reported on 1 October 2026 a consensus target of $23.36 from 17 brokerages, with 14 buy ratings, 1 strong buy, 1 hold and 1 sell. Morgan Stanley raised its target to $18 from $17 on 6 August 2026, per Benzinga.

Bear case

• The shares sit well below September levels. The close on 27 October 2026 is $11.81, against $14.04 on 8 September 2026 per Benzinga, the day before the durability release. No negative company event dated since then explains the gap.
• Share issuance remains possible. An automatic mixed securities registration statement has been on file since 5 August 2026, and no priced offering has been disclosed. A sale around NDA completion would add to the 135,722,306 ordinary shares reported at 30 June 2026.
• Approval does not open the market at once. Nath said on 22 September 2026 that Drug Enforcement Administration (DEA) rescheduling of psilocybin could take 1 to 90 days after approval. He described a measured initial launch.
• The lowest target is near the price. Wells Fargo's Hold rating carries a $13 target, the lowest published, per Investing.com and MarketBeat in August 2026. The last close is $11.81.
• The filing date is still unconfirmed. Management guided to Q4 2026 and has announced no completion date. Any change in that language on 3 November 2026 would hit the central event.

Price setup

The adjusted daily close was $11.81 on 27 October 2026. That is 22.3% below the 52-week high of $15.19 and 2.1% higher than three months earlier. The close on 14 October 2026 was $11.27.

MarketBeat reported a 50-day moving average of $13.38 and a 200-day moving average of $11.21 on 1 October 2026. The latest close is above the 200-day figure as reported then and below the 50-day. Neither average has been re-measured since.

Crowding evidence is mixed. Coverage is broad at 17 brokerages. An imminent earnings date on 3 November 2026 and an open registration statement for new shares are both observable. No Form 4 insider sales were found in the sources reviewed.

Catalysts, next 30 days

• ~31 December 2026, est.: Rolling NDA completion. This falls after the 30-day window and is the event the case turns on. Completion starts the one-to-two-month voucher review target.

Elapsed catalysts

• 3 November 2026: Q3 2026 results. The company announced the date on 27 October 2026. The report shows the share count, the cash position and whether Q4 NDA completion is still guided. (passed 3d ago)

What would change the view

The case breaks if the company moves NDA completion past Q4 2026, if the FDA assigns a standard review clock or issues a refuse-to-file letter, or if an 8-K discloses adverse FDA correspondence. A priced equity offering that lifts the share count well above 135,722,306 would weaken it. DEA scheduling that lags approval by more than the 90 days Nath cited on 22 September 2026 would push back commercial dispensing.

On price, a daily close below $11.20, just under the $11.21 200-day moving average MarketBeat reported on 1 October 2026, would show selling that outweighs the regulatory record. A close above the 50-day moving average would show the market gaining confidence in the filing timetable.

What it trades with

Compass trades on its own regulatory path and on sentiment toward psychedelic medicines. Results from other developers in the area can move the shares without any Compass news. Quarterly remeasurement of warrant liabilities moves reported earnings per share inversely to the share price. Broad small-cap biotech funding conditions affect the odds and pricing of any equity raise.